The Evolution of Targeted Degradation

Targeted protein degradation (TPD) represents one of the most significant therapeutic innovations in oncology. While traditional small-molecule inhibitors must bind to active sites to block protein function, targeted degraders—specifically Proteolysis-Targeting Chimeras (PROTACs) and molecular glues—recruit the cell's own ubiquitin-proteasome machinery to systematically destroy the disease-causing protein.

For years, the clinical validation of TPD was concentrated in haematological cancers. However, the sector is experiencing a major expansion as candidates enter clinical trials for solid tumours, targeting historically "undruggable" oncogenic proteins. Moving these large, bi-functional molecules into solid tumour trials requires a rigorous translational strategy and specialised clinical leadership.

Validating the Modality: Clinical Milestones

The clinical and regulatory viability of PROTACs in solid tumours has achieved critical validation through several advanced candidates:

• Vepdegestrant (ARV-471): Developed for ER+/HER2− breast cancer, this estrogen receptor-degrading PROTAC demonstrated significant progression-free survival benefits. Following priority review, it is progressing rapidly through the global regulatory approval pipeline, serving as a landmark precedent for PROTAC efficacy in solid oncology.

• Diversifying E3 Ligases: Historically, degraders have relied almost exclusively on Cereblon (CRBN) or Von Hippel-Lindau (VHL) E3 ligases. In 2025, drug developers are increasingly utilising structural biology and AI-driven drug design to identify novel E3 ligase binders, aiming to circumvent resistance mechanisms and broaden the targetable proteome.

• Molecular Glue Progress: Candidates like ST-01156 have secured FDA IND clearances to initiate Phase I investigations in advanced solid tumours, demonstrating the industry's ability to develop smaller, more orally bioavailable degraders.

The Translational Challenge: PK/PD and Biomarker Development

Advancing targeted degraders into solid tumour trials presents unique pharmacological complexities that traditional oncology drugs do not share:

• The Hook Effect: Because PROTACs function catalytically (one degrader molecule can destroy multiple target proteins), they exhibit a non-linear pharmacodynamic profile. At excessively high doses, binary complexes form rather than the active ternary complex, reducing degradation efficiency. Translational teams must carefully model this "hook effect" to define the optimal biological dose rather than the maximum tolerated dose.

• Target and Ligase Expression: Success in solid tumours depends on confirming that both the target oncogenic protein and the recruited E3 ligase are expressed in the tumour microenvironment.

• Biomarker Assays: Developing quantitative assays to measure target protein degradation in patient biopsies is critical to demonstrating early proof-of-mechanism.

The Talent Profile: Scoping the Translational Medicine Director

Entering Phase I/II solid tumour trials requires a highly specialised Translational Medicine Director with direct experience in protein degradation. General oncology drug developers often struggle with the catalytic pharmacology and complex PK/PD relationships of TPD.

RSA has identified the essential competencies for translational leaders in this space:

• TPD Pharmacological Fluency: A deep scientific background in ubiquitin-proteasome biology, ternary complex kinetics, and E3 ligase recruitment.

• Biomarker Assay Engineering: A proven track record in developing and validating pharmacodynamic biomarker assays (e.g., quantitative western blot, mass spectrometry) for solid tumour tissues.

• Strategic Phase I Design: Experience in designing first-in-human dose-escalation protocols that account for non-linear PK/PD modeling, satisfying regulatory safety standards while optimizing therapeutic efficacy.

As pharmaceutical organisations invest billions in TPD licensing agreements, securing translational directors who can navigate the operational and scientific complexities of solid tumour trials is the primary driver of portfolio value.